▶주메뉴 바로가기
▶본문 바로가기
Celltrion said Wednesday it has signed a license-in agreement with Korean biopharma company KoBioLabs for three microbiome-based drug candidates targeting intestinal diseases. The signing ceremony was held at Celltrion’s Global Biotechnology Research Center, attended by Executive Vice President Seo Jin-seok and KoBioLabs CEO Ko Kwang-pyo. Under the deal, valued at up to 205.2 billion won ($136.8 million), Celltrion secured exclusive rights to develop and commercialize KoBioLabs candidates KC84,
Celltrion said Tuesday it will invest 1.23 trillion won ($820 million) to build two new plants in Songdo, Incheon, bolstering its capacity by 180,000 liters amid the increasing global demand. According to the Korean biosimilar producer, the investment will be carried out in phases through 2030 to support the company’s production and supply of next-generation biosimilar and drug candidates while expanding its contract manufacturing organization, or CMO, business worldwide. Celltrion also announce
Cha Biotech said Thursday it will transfer 8.95 million shares in Cha Vaccine Institute, worth 23.8 billion won ($15.8 million), to Solux, AriBio Investment Purpose No. 13 and other investors. Following the deal, Cha Biotech’s stake in the Kosdaq-listed affiliate will fall to 1.34 million shares, or 4.99 percent, marking a strategic exit from management control while retaining a minority stake for future collaboration. The proceeds will be used to strengthen core growth areas, including cell and
SK Bioscience said Wednesday it has secured funding from the Research Investment for Global Health Technology Foundation to advance the clinical development of RSM01, a monoclonal antibody candidate aimed at preventing respiratory syncytial virus, strengthening its presence in the global infectious disease market. According to SK Bioscience, the RIGHT Foundation agreed to provide 4 billion won ($2.7 million) — the largest grant available per project — to the Korean vaccine developer. With the fu
Celltrion said Tuesday it has signed a 294.9 billion won ($198 million) contract manufacturing agreement with an undisclosed global pharmaceutical company to supply drug substance. The three-year deal runs from 2027 to 2029 and includes an option to expand to 375.4 billion won upon mutual agreement. The contract underscores Celltrion’s accelerating push into the global contract development and manufacturing organization market. Earlier this year, the company signed a 678.7 billion won CMO deal w
China’s biopharmaceutical and biotechnology companies are rapidly expanding their global presence, driven not only by strong drug pipelines but also by increasingly aggressive outreach to international partners, according to a China industry expert. “If you look at the first two months of licensing or cross-border deals from Chinese innovators, the volume has already exceeded that of the first quarter last year,” said Fangning Zhang, a partner at McKinsey & Company’s Shanghai office, in an inter
Celltrion said Friday it will immediately apply newly eased US biosimilar development rules to its pipeline, a move expected to cut development costs and shorten timelines. The decision follows the recent release of the fourth revision of the biosimilar development Q&A guidelines by the US Food and Drug Administration, which simplifies pharmacokinetic testing requirements for biosimilars. A key change in the revision relaxes the criteria for reference drugs used in clinical comparisons. Previous
Samsung Biologics has highlighted its contract development and manufacturing organization, or CDMO, capabilities at Biologics Manufacturing Asia 2026 in Singapore, receiving a bioprocessing excellence award during the two-day event. According to Samsung Biologics on Thursday, the Korean CDMO leader presented its top-notch CDO technologies and services at the conference on Wednesday. Lim Heon-chang, director of formulation development at Samsung Biologics’ CDO division, introduced case studies of
Samsung Biologics has teamed up with Eli Lilly to set up an open innovation hub for emerging biotechnology companies in Korea, marking the first time for Eli Lilly to establish such a site outside the United States and China. According to Samsung Biologics on Tuesday, the two companies agreed to build a Lilly Gateway Labs site within the Korean contract development and manufacturing organization, or CDMO, leader’s second bio campus in Songdo, Incheon. The LGL facility will consist of five storie
Celltrion said Monday it continues to see solid prescription growth across Asian markets, with several of its key biosimilar products capturing leading market shares. Its flagship autoimmune disease treatment Remsima has established a dominant presence in multiple markets. According to clinical research provider IQVIA, as of the third quarter of 2025 Remsima held market shares of 93 percent in Singapore, 77 percent in Hong Kong, 73 percent in Thailand and 65 percent in Malaysia. Another autoimmu
Chipotle bets on Korea for first bite of Asia
Samsung vs. LG battle for AI cooling heats up
Musinsa posts record earnings on offline, global expansion
One purchase every 0.9 second: Olive Young foreign sales top W1tr
Samsung, SK hynix tax payments surge 167% on chip boom
SK Chemicals eyes European can-coating market
Sept. 2, 2026
March 25, 2026
March 24, 2026
March 19, 2026
March 18, 2026
March 17, 2026
March 16, 2026
March 13, 2026
March 12, 2026
March 11, 2026
March 9, 2026
